Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Other Operating Expenses (2010 - 2024)

Perspective Therapeutics' (CATX) quarterly Other Operating Expenses came in at $32000.0 in Q4 2024, up 45.45% year-over-year from $22000.0 in Q1 2024, and up 152.46% quarter-over-quarter from -$61000.0 in Q2 2024.

Analysis

Perspective Therapeutics (CATX) Other Operating Expenses (2010 - 2024) Analysis & Trends

Perspective Therapeutics has disclosed Other Operating Expenses across 15 years of filings, most recently posting $32000.0 for Q4 2024.

  • In Q4 2024, Other Operating Expenses rose 45.45% year-over-year to $32000.0; the TTM figure through Mar 2026 stood at $32000.0 (up 210.34% YoY), while the FY2024 annual figure was -$27000.0, changed N/A from the prior year.
  • Other Operating Expenses came in at $32000.0 for Q4 2024 at Perspective Therapeutics, up from -$61000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.3 million in Q2 2022 to a low of -$305000.0 in Q4 2022.
  • Average Other Operating Expenses over 5 years is $219000.0, with a median of $27000.0 recorded in 2023.
  • The largest YoY upside for Other Operating Expenses was 29300.0% in 2020 against a maximum downside of 102.53% in 2020.
  • Over 5 years, Other Operating Expenses stood at -$7000.0 in 2020, then soared by 10128.57% to $702000.0 in 2021, then sank by 143.45% to -$305000.0 in 2022, then soared by 107.21% to $22000.0 in 2023, then surged by 45.45% to $32000.0 in 2024.
  • Per Business Quant data, the three most recent Other Operating Expenses figures were $32000.0 in Q4 2024, -$61000.0 in Q2 2024, and $22000.0 in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Perspective Therapeutics 361.95 Mn 361.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 32,000.00
Jun 30, 2024 -61,000.00
Dec 31, 2023 22,000.00
Mar 31, 2023 -22,000.00
Dec 31, 2022 -305,000.00
Jun 30, 2022 1.34 Mn
Sep 30, 2021 702,000.00
Mar 31, 2021 -2,000.00
Dec 31, 2020 -7,000.00
Sep 30, 2020 312,000.00
Jun 30, 2020 322,000.00
Mar 31, 2020 294,000.00
Dec 31, 2019 277,000.00
Sep 30, 2019 160,000.00
Mar 31, 2019 1,000.00
Dec 31, 2018 23,000.00
Sep 30, 2018 420,000.00
Jun 30, 2018 572,000.00
Mar 31, 2018 473,000.00
Dec 31, 2017 340,000.00